Literature DB >> 32974724

Prognostic Value of Change in Cardiac Index After Prostacyclin Initiation in Pediatric Pulmonary Hypertension.

Patrick D Evers1, Paul J Critser2, Michelle Cash2, Melissa Magness2, Russel Hirsch2,3.   

Abstract

Invasive hemodynamic assessment remains the gold standard for the diagnosis of pediatric pulmonary hypertension and for longitudinal assessment of response to therapy. This analysis sought to describe the changes in hemodynamic variables after initiation of prostacyclin therapy and determine which changes bear predictive power of adverse clinical outcomes. A retrospective chart review of established patients at Cincinnati Children's Hospital with pulmonary arterial hypertension (PAH) who required prostacyclin therapy between 2004 and 2018 was performed. The baseline hemodynamic parameters at diagnosis as well as change in those parameters between initial catheterization and post-prostacyclin initiation catheterization were independent variables. Cox proportional hazard regression and recursive partitioning analysis were used to characterize which hemodynamic factors predicted the composite adverse outcome (CAO) defined as death, lung transplantation, or reverse Pott's shunt surgery. During the study period, 29 patients met inclusion criteria in which there were 7 CAOs: 4 deaths, 3 lung transplants, and 2 reverse Pott's shunts. Median time between catheterizations was 86 days and between the initiation of prostacyclin therapy and the second catheterization was 54 days. Cox regression revealed that only baseline pulmonary artery pressure (> 51 mmHg) and a failure to increase cardiac index illustrated statistically significant hazard for occurrence of the CAO (p < 0.01). These criteria significantly dichotomized the population in a Kaplan-Meier analysis into likelihoods of experiencing the CAO. While controlling for other hemodynamic variables, the absence of augmentation of cardiac index after the initiation of prostacyclin therapy is a valuable prognostic indicator of adverse PAH outcomes in pediatrics.

Entities:  

Keywords:  Epoprostenol; Hemodynamics; Hypertension; Pediatrics; pulmonary

Mesh:

Substances:

Year:  2020        PMID: 32974724     DOI: 10.1007/s00246-020-02460-6

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  18 in total

1.  Response: Still puzzling about a clear definition of pulmonary arterial hypertension in newborns.

Authors:  Erika B Rosenzweig; Steven H Abman; Rolf M F Berger
Journal:  Eur Respir J       Date:  2019-03-28       Impact factor: 16.671

2.  Clinical features of paediatric pulmonary hypertension: a registry study.

Authors:  Rolf M F Berger; Maurice Beghetti; Tilman Humpl; Gary E Raskob; D Dunbar Ivy; Zhi-Cheng Jing; Damien Bonnet; Ingram Schulze-Neick; Robyn J Barst
Journal:  Lancet       Date:  2012-01-11       Impact factor: 79.321

3.  A roadmap for management of chronic thromboembolic pulmonary hypertension.

Authors:  Xavier Jaïs; Philippe Brenot; David Montani; Elie Fadel; Marc Humbert; Gérald Simonneau
Journal:  Eur Respir J       Date:  2019-10-24       Impact factor: 16.671

4.  Assessing pulmonary hypertensive vascular disease in childhood. Data from the Spanish registry.

Authors:  M J del Cerro Marín; A Sabaté Rotés; A Rodriguez Ogando; A Mendoza Soto; M Quero Jiménez; J L Gavilán Camacho; I Raposo Sonnenfeld; A Moya Bonora; D C Albert Brotons; A Moreno Galdó
Journal:  Am J Respir Crit Care Med       Date:  2014-12-15       Impact factor: 21.405

5.  Cardiac catheterization in children with pulmonary hypertensive vascular disease.

Authors:  Prashant Bobhate; Long Guo; Shreepal Jain; Richard Haugen; James Y Coe; Dominic Cave; Jennifer Rutledge; Ian Adatia
Journal:  Pediatr Cardiol       Date:  2015-01-11       Impact factor: 1.655

6.  Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.

Authors:  Olivier Sitbon; Marc Humbert; Hilario Nunes; Florence Parent; Gilles Garcia; Philippe Hervé; Maurizio Rainisio; Gérald Simonneau
Journal:  J Am Coll Cardiol       Date:  2002-08-21       Impact factor: 24.094

7.  Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

Authors:  G E D'Alonzo; R J Barst; S M Ayres; E H Bergofsky; B H Brundage; K M Detre; A P Fishman; R M Goldring; B M Groves; J T Kernis
Journal:  Ann Intern Med       Date:  1991-09-01       Impact factor: 25.391

8.  Primary pulmonary hypertension in children: clinical characterization and survival.

Authors:  J Sandoval; O Bauerle; A Gomez; A Palomar; M L Martínez Guerra; M E Furuya
Journal:  J Am Coll Cardiol       Date:  1995-02       Impact factor: 24.094

9.  Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society.

Authors:  Steven H Abman; Georg Hansmann; Stephen L Archer; D Dunbar Ivy; Ian Adatia; Wendy K Chung; Brian D Hanna; Erika B Rosenzweig; J Usha Raj; David Cornfield; Kurt R Stenmark; Robin Steinhorn; Bernard Thébaud; Jeffrey R Fineman; Titus Kuehne; Jeffrey A Feinstein; Mark K Friedberg; Michael Earing; Robyn J Barst; Roberta L Keller; John P Kinsella; Mary Mullen; Robin Deterding; Thomas Kulik; George Mallory; Tilman Humpl; David L Wessel
Journal:  Circulation       Date:  2015-11-03       Impact factor: 29.690

10.  2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT.

Authors:  Georg Hansmann; Martin Koestenberger; Tero-Pekka Alastalo; Christian Apitz; Eric D Austin; Damien Bonnet; Werner Budts; Michele D'Alto; Michael A Gatzoulis; Babar S Hasan; Rainer Kozlik-Feldmann; R Krishna Kumar; Astrid E Lammers; Heiner Latus; Ina Michel-Behnke; Oliver Miera; Nicholas W Morrell; Guido Pieles; Daniel Quandt; Hannes Sallmon; Dietmar Schranz; Karin Tran-Lundmark; Robert M R Tulloh; Gregor Warnecke; Håkan Wåhlander; Sven C Weber; Peter Zartner
Journal:  J Heart Lung Transplant       Date:  2019-06-21       Impact factor: 10.247

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.